Bridging Therapy

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, Janssen Research & Development, LLC, Oncternal Therapeutics, Inc, Universität Münster

Conditions

B-cell Lymphoma RecurrentB-cell Lymphoma RefractoryNon-Hodgkin LymphomaProstatic NeoplasmsRelapsed/Refractory Aggressive B-Cell Malignancies

Phase 1

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Active, not recruitingNCT05022849

Janssen Research & Development, LLCProstatic Neoplasms

Start: 2021-09-28End: 2037-10-30Updated: 2026-03-13

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

TerminatedNCT05588440

Oncternal Therapeutics, IncRelapsed/Refractory Aggressive B-Cell Malignancies

Start: 2023-05-09End: 2024-09-12Updated: 2024-12-05

Phase 2

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

CompletedNCT03610724

Novartis PharmaceuticalsNon-Hodgkin Lymphoma

Start: 2019-02-15End: 2023-04-26Updated: 2024-06-20

Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma

TerminatedNCT06912529

Universität MünsterB-cell Lymphoma Recurrent, B-cell Lymphoma Refractory

Start: 2025-03-13End: 2025-07-25Updated: 2025-09-04

Related Papers

Trial-in-Progress: A Phase 1/2 Multi-Center Study of Onct-808, a ROR1-Specific CAR T, in Adult Patients with Relapsed/Refractory Aggressive B Cell Lymphoma

Blood2023-11-026 citations

Anti-ROR1 CAR-T cells: Architecture and performance.

2023-02-1715 citations

S255: EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDY

HemaSphere2022-06-014 citations

Primary mediastinal large B‐cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy

British Journal of Haematology2020-05-296 citations

Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).

Journal of Clinical Oncology2020-05-206 citations

BIANCA: A PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF TISAGENLECLEUCEL IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY MATURE B‐CELL NON‐HODGKIN LYMPHOMA

Hematological Oncology2019-06-011 citations